Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Patients will receive magrolimab in combination with "7+3" or CPX-351 at:

* Day 1, 4: IV 1 mg/kg * Day 8: IV 15 mg/kg * Day 11, 15 and 22: IV 30 mg/kg * Followed by weekly doses for 5 weeks and then q2w until the end of consolidation

If "7+3":

* Induction cycle 1 (IND 1): * Cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours * Daunorubicin at 60 mg/m² on study days 3, 4, 5 * Induction cycle 2 (IND 2, optional): * Cytarabine at 100 mg/m² on days 1-7 of the second induction cycle (i.e. study days 29-35) as a continuous infusion over 22-24 hours * Daunorubicin at 60 mg/m² on days 3, 4, 5 of the second induction cycle (i.e. study days 31, 32, 33) * Consolidation cycle (CONS, optional): * Cytarabine at 1 g/m² administered on days 1, 3, 5 of each consolidation cycle as an infusion for 2 hours every 12 hours (for patients \< 60 years up to 3 CONS cycles and for patients ≥ 60 years up to 2 CONS cycles)

If CPX-351:

* Induction cycle 1 (IND 1): CPX-351 (fixed combination daunorubicin 44 mg/m² and cytarabine 100 mg/m²) days 1, 3, 5 * Induction cycle 2 (IND 2, optional): CPX-351 (fixed combination daunorubicin 44 mg/m² and cytarabine 100 mg/m²) days 1, 3 (i.e. study days 29, 30) * Consolidation cycle 1 (CONS, optional): CPX-351 (fixed combination daunorubicin 29 mg/m² and cytarabine 65 mg/m²) days 1, 3